BridgeBio Pharma (NASDAQ:BBIO) inks a collaboration agreement with Catalent (NYSE:CTLT) for gene therapy development and manufacturing at the latter’s Harmans, MD facility. Specifically, the partnership is aimed at supporting clinical and commercial demand for the former’s gene therapy candidates BBP-631, BBP-812, for congenital adrenal hyperplasia and Canavan disease.
Financial terms are not disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.